Effect of Nintedanib on Progression of Systemic Sclerosis-Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled Trial.

Shervin AssassiOliver DistlerYannick AllanoreTakashi OguraJohn VargaSerena VettoriBruno CrestaniFlorian VossMargarida AlvesSusanne StowasserToby M Mahernull null

Published in: ACR open rheumatology (2022)

Nintedanib provides a sustained benefit on slowing the progression of SSc-ILD over 100 weeks, with adverse events that are manageable for most patients.

Keyphrases

interstitial lung disease
systemic sclerosis
idiopathic pulmonary fibrosis
rheumatoid arthritis
end stage renal disease
newly diagnosed
chronic kidney disease
electronic health record
big data
machine learning
patient reported outcomes
deep learning
artificial intelligence
data analysis
patient reported